Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Small Molecule Inhibition of Neuroserpin to Restore Nerve Growth Factor Maturation in Alzheimer’s Disease

FY 2024-25

Summary
Around the world, someone develops dementia every 3 seconds, and in 2020, 55 million people were living with dementia, with numbers expected to double every 20 years, particularly in developing countries. These statistics highlight the urgent need for effective and early treatments for Alzheimer's Disease (AD), the most common cause of dementia. One theory, known as the cholinergic hypothesis, suggests that AD results from the loss of cholinergic neurons, which are critical for memory and learning.Recent research from our laboratory has uncovered a new cellular pathway that regulates the levels of nerve growth factor (NGF), a protein that supports cholinergic neuron survival and function. We discovered that neuroserpin, a protein, indirectly prevents NGF from becoming fully active, and this blockage is more common in individuals with AD. Our project aims to develop small molecule drugs that block neuroserpin, enabling NGF to fully activate and protect neurons. If successful, we could prevent neuron damage and death, potentially improving memory and learning in individuals with AD.Using computer-based drug design and biological testing, we will identify and validate neuroserpin inhibitors and assess their efficacy in Wistar rat brain tissue and in living transgenic rat models. By promoting NGF availability, we aim to prevent neuron degeneration, protect cholinergic neurons from further damage, and preserve normal cognitive functions. This innovative approach is especially significant because no neuroserpin inhibitors are currently commercially available. Through this therapeutic, we seek to address the underlying causes of neuron loss in AD and provide a novel approach to slowing or preventing disease progression.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530023
Name
Parmar Abhay
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Small Molecule Inhibition of Neuroserpin to Restore Nerve Growth Factor Maturation in Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Drug Discovery; In-Silico Docking; Neuroserpin; Ngf Metabolic Pathway; Small Molecule; Structure Activity Relationships; Therapeutics; Transgenic Rat Model
Abstract
Around the world, someone develops dementia every 3 seconds, and in 2020, 55 million people were living with dementia, with numbers expected to double every 20 years, particularly in developing countries. These statistics highlight the urgent need for effective and early treatments for Alzheimer's Disease (AD), the most common cause of dementia. One theory, known as the cholinergic hypothesis, suggests that AD results from the loss of cholinergic neurons, which are critical for memory and learning.Recent research from our laboratory has uncovered a new cellular pathway that regulates the levels of nerve growth factor (NGF), a protein that supports cholinergic neuron survival and function. We discovered that neuroserpin, a protein, indirectly prevents NGF from becoming fully active, and this blockage is more common in individuals with AD. Our project aims to develop small molecule drugs that block neuroserpin, enabling NGF to fully activate and protect neurons. If successful, we could prevent neuron damage and death, potentially improving memory and learning in individuals with AD.Using computer-based drug design and biological testing, we will identify and validate neuroserpin inhibitors and assess their efficacy in Wistar rat brain tissue and in living transgenic rat models. By promoting NGF availability, we aim to prevent neuron degeneration, protect cholinergic neurons from further damage, and preserve normal cognitive functions. This innovative approach is especially significant because no neuroserpin inhibitors are currently commercially available. Through this therapeutic, we seek to address the underlying causes of neuron loss in AD and provide a novel approach to slowing or preventing disease progression.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parmar, Abhay
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~